ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.>
ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On June 1, 2017, the company announced that Derica W. Rice, executive vice president and chief financial officer, informed the board of directors of his intent to retire from the company, effective December 31, 2017. The company is conducting an internal and external search to identify Mr. Rice’s replacement.
A copy of the press release announcing Mr. Rice’s retirement is filed as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
Exhibit Number Description
99.1 Press release dated June 1, 2017.
About ELI LILLY AND COMPANY (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products. ELI LILLY AND COMPANY (NYSE:LLY) Recent Trading Information
ELI LILLY AND COMPANY (NYSE:LLY) closed its last trading session up +1.23 at 79.57 with 5,163,876 shares trading hands.
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products. ELI LILLY AND COMPANY (NYSE:LLY) Recent Trading Information
ELI LILLY AND COMPANY (NYSE:LLY) closed its last trading session up +1.23 at 79.57 with 5,163,876 shares trading hands.